Finding the right balance between cancer-induced fatigue and immune-oncology–induced fatigue and doing enough exercise to improve general health and better cancer outcomes is a fundamental part of treating patients with cancer. Finding this balance for patients with NSCLC receiving immune-oncology therapy is a key element of overall care for these patients. Read More ›

Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant sotorasib accelerated approval for patients with KRAS^G12C mutation–positive NSCLC. Read More ›

Sotorasib showed encouraging anticancer activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC. Read More ›

Immunotherapy and targeted therapy have resulted in improved survival rates in patients with NSCLC over the past decade. Read More ›

Multidisciplinary tumor board members work closely to make the best clinical decisions for their patients with cancer to improve patient and institutional outcomes. Their decisions should be based on the clinical data of each patient in line with their own clinical and institutional guidelines. Read More ›

Patritumab deruxtecan (HER3-DxD), an investigational antibody–drug conjugate targeting the HER3 growth factor receptor, showed promising activity in patients with locally advanced or metastatic EGFR mutation–positive non–small-cell lung cancer (NSCLC) who had received previous EGFR tyrosine kinase inhibitor (TKI) therapy, according to interim results from a phase 1 dose-­escalation and dose-expansion trial. Read More ›

Dual EGFR targeting with amivantamab-vmjw (Rybrevant) plus lazertinib (Leclaza) led to durable responses in more than one-third of chemotherapy-naïve patients with EGFR-positive non–small-cell lung cancer (NSCLC) whose disease had progressed on osimertinib (Tagrisso) therapy, according to a cohort analysis of the CHRYSALIS trial, presented at the American Society of Clinical Oncology 2021 virtual annual meeting. The study also provided insights into resistance mechanisms in patients previously treated with osimertinib. Read More ›

On September 15, 2021, the FDA accelerated the approval of mobocertinib (Exkivity; Takeda), an oral kinase inhibitor, for adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease progressed during or after platinum-based chemotherapy. Mobocertinib received breakthrough therapy and orphan drug designations for this indication. Read More ›

Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved pathologic complete response (pCR) rates versus chemotherapy alone in patients with resectable stage IB-IIIA non–small-cell lung cancer (NSCLC), according to final results from the CheckMate-816 clinical trial. Read More ›

Approximately 13% of patients with lung adenocarcinoma harbor the KRAS p.G12C mutation, which is associated with poor clinical outcomes. During the American Society of Clinical Oncology 2021 virtual annual meeting, Ferdinandos Skoulidis, MD, PhD, MRCP, Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, provided updated results from the phase 2 component of the CodeBreaK 100 clinical trial Read More ›